DEVELOP OF ANTIBODY FRAGM AS CONTR AGT FOR MRI OF ALZH?S DIS AMYLOID PLAQUES

开发抗体片段作为 ALZH 淀粉样斑块 MRI 的对照 AGT

• 批准号: 8362868
• 负责人: MICHAEL GARWOOD
• 金额: $ 3.03万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-06-01 至 2012-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8362868
• 关键词: Alzheimer' s Disease; Amyloid; Antibodies; Blood; Brain; Contrast Media; Diagnostic; Early Diagnosis; Funding; Grant; Human; Image; Lead; Magnetic Resonance; Magnetic Resonance Imaging; Measures; Modification; Monoclonal Antibodies; NMR Spectroscopy; National Center for Research Resources; Nerve; Nervous system structure; Principal Investigator; Proteins; Research; Research Infrastructure; Resources; Senile Plaques; Source; Testing; Transgenic Mice; United States National Institutes of Health; cost; in vivo; molecular imaging; therapeutic target

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The ability to target therapeutic or diagnostic proteins to the nervous system is limited by the presence of the blood-brain/nerve barriers. In this project we are testing the hypothesis that modifications of an F(ab2)2 fragment of a monoclonal antibody (IgG4.1) against fibrillar human A¿42 can be used for the molecular imaging of amyloid plaques in Alzheimer's disease (AD) using high field strength magnetic resonance microimaging (MRMI) (9.4 T). The ability of this contrast agent to image plaques in vivo in AD transgenic mice may lead to early diagnosis of AD in humans and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed.

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 将治疗或诊断蛋白靶向神经系统的能力受到血-脑/神经屏障的存在的限制。在这个项目中，我们正在测试这样一个假设，即针对纤维状人Aé42的单抗(IgG4.1)的F(AB2)2片段的修饰可以用于使用高场强磁共振显微成像(MRMI)(9.4T)对阿尔茨海默病(AD)中的淀粉样斑块进行分子成像。这种造影剂在AD转基因小鼠体内成像斑块的能力可能会导致人类早期诊断AD，也提供了目前正在开发的抗淀粉样蛋白疗法的疗效的直接衡量标准。